Assisting dementia diagnosis through the electrochemical immunosensing of glial fibrillary acidic protein

• Published in: Talanta (Oxford) Vol. 246; p. 123526
• Main Authors: Ozcelikay, Goksu, Gamella, María, Unal, Mehmet Altay, Gucuyener, Kıvılcım, Montero-Calle, Ana, Barderas, Rodrigo, Pingarrón, José M., Campuzano, Susana, Ozkan, Sibel A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.08.2022
• Subjects: Alzheimer disease; antibodies; blood serum; brain; Brain tissue extracts; carbon; carboxylic acids; cerebrospinal fluid; detection limit; electrochemistry; enzyme-linked immunosorbent assay; GFAP; hydrogen peroxide; hydroquinone; Immunoplatform; magnetism; MBs; microbeads; prognosis; Immunoplatform; Brain tissue extracts; Alzheimer disease; GFAP; MBs
• ISSN: 0039-9140; 1873-3573; 1873-3573
• DOI: 10.1016/j.talanta.2022.123526

Glial fibrillary acidic protein (GFAP) is a member of the intermediate filament family of proteins with increased levels in serum and cerebrospinal fluid of patients with Alzheimer disease (AD) and other neurodegenerative diseases (NDs), such as vascular dementia (VD). This work describes the first magnetic microbeads (MBs)-based electrochemical immunoplatform for GFAP determination. The platform design comprises a sandwich immunoassay implemented on the MBs surface and amperometric transduction at single-use screen-printed carbon electrodes (SPCEs). Micro-sized carboxylic acid magnetic particles (COOH-MBs) were modified with a specific capture antibody (CAb) to selectively link the target protein, which was sandwiched with a biotinylated detector antibody (btn-DAb) further conjugated with a streptavidin-peroxidase (Strep-HRP) conjugate. Amperometric transduction was performed at SPCEs upon capturing the magnetic bioconjugates on their surface and through the hydrogen peroxide/hydroquinone (H2O2/HQ) system. The immunoplatform achieved a limit of detection of 67 pg mL−1 for the amperometric detection of standards and selectivity compatible with clinical applicability to assist in minimally invasive NDs diagnosis and prognosis. The MBs-based immunoplatform was applied with good results to determine the endogenous content of GFAP in protein brain extracts without matrix effect and using just 6.25 ng of sample per determination. Furthermore, the developed methodology was capable of differentiating between healthy subjects and patients diagnosed with VD and AD in only 2 h, providing accurate results in line with those obtained by an ELISA kit that used the same immunoreagents. [Display omitted] •First magnetic beads-based immunosensor for GFAP determination.•Amperometric detection at screen-printed carbon electrodes.•Sensitivity (LOD of 67 pg mL−1) and selectivity compatible with clinical applicability.•Discrimination of patients with Alzheimer's disease by analyzing brain extracts.